Emicizumab and thrombosis: The story so far-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emicizumab and thrombosis: The story so far

Published:2019-07-31 Issue:8 Volume:17 Page:1269-1272
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Makris Michael¹²^ORCID,Iorio Alfonso³^ORCID,Lenting Peter J.⁴

Affiliation:

1. Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK

2. Sheffield Haemophilia and Thrombosis Centre Royal Hallamshire Hospital Sheffield UK

3. Department of Epidemiology and Biostatistics McMaster University Hamilton Ontario Canada

4. INSERM U1176 Universite Paris‐Sud Le Kremlin‐Bicetre France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14556

Reference14 articles.

1. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

2. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

3. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy

4. Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A

5. Available fromwww.emicizumabinfo.com[accessed 12 June 2019].

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.;Journal of Thrombosis and Haemostasis;2024-09

2. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data;Journal of Thrombosis and Haemostasis;2024-06

3. Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab;Cureus;2024-04-24

4. Challenges in ageing persons with haemophilia;Haemophilia;2024-03-27

5. Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India;Heliyon;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3